Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2007-09-05 15:23:44 UTC |
---|
Update Date | 2022-11-30 19:02:48 UTC |
---|
HMDB ID | HMDB0006728 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | CE(24:1(15Z)) |
---|
Description | Cholesteryl nervonic acid is a cholesteryl ester. A cholesteryl ester is an ester of cholesterol. Fatty acid esters of cholesterol constitute about two-thirds of the cholesterol in the plasma. Cholesterol is a sterol (a combination steroid and alcohol) and a lipid found in the cell membranes of all body tissues, and transported in the blood plasma of all animals. The accumulation of cholesterol esters in the arterial intima (the innermost layer of an artery, in direct contact with the flowing blood) is a characteristic feature of atherosclerosis. Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part to the deposition of lipoproteins (plasma proteins that carry cholesterol and triglycerides). Placental membrane changes in permeability to water, urea and mannitol in intrauterine growth restriction are related to changes in cholesterol fatty acid content of the membranes with a predominance of saturated fatty acid species such as nervonic acid. Nervonic acid may have preventive effects on obesity-related metabolic disorders. Lower levels of nervonic acid are found in all plasma lipid fractions from infants fed formula compared with those in the human milk-fed infants, irrespective of the source of the formula supplement. (PMID: 16394593 , 10446293 , 15051839 ). |
---|
Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)[C@H](C)CCCC(C)C InChI=1S/C51H90O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-31-49(52)53-44-36-38-50(5)43(40-44)32-33-45-47-35-34-46(42(4)30-28-29-41(2)3)51(47,6)39-37-48(45)50/h14-15,32,41-42,44-48H,7-13,16-31,33-40H2,1-6H3/b15-14-/t42-,44+,45+,46-,47+,48+,50+,51-/m1/s1 |
---|
Synonyms | Value | Source |
---|
24:1 Cholesterol ester | HMDB | Cholest-5-en-3beta-yl (15Z-tetracosenoate | HMDB | Cholest-5-en-3beta-yl (15Z-tetracosenoate) | HMDB | Cholest-5-en-3beta-yl (15Z-tetracosenoic acid | HMDB | Cholesteryl nervonic acid | HMDB | Cholesterol 1-nervonoate | HMDB | 24:1(15Z) Cholesterol ester | HMDB | Cholesterol ester(24:1/0:0) | HMDB | Cholesteryl 1-nervonoate | HMDB | CE(24:1) | HMDB | CE(24:1/0:0) | HMDB | Cholesterol ester(24:1) | HMDB | Cholesteryl 1-(15Z-tetracosanoate) | HMDB | 1-Nervonoyl-cholesterol | HMDB | Cholesterol 1-nervonoic acid | HMDB | Cholesterol 1-(15Z-tetracosanoic acid) | HMDB | Cholesterol 1-(15Z-tetracosanoate) | HMDB | Cholesteryl 1-(15Z-tetracosanoic acid) | HMDB | 1-(15Z-Tetracosanoyl)-cholesterol | HMDB | Cholesteryl 1-nervonoic acid | HMDB | CE(24:1(15Z)) | Lipid Annotator | (1S,2R,5S,10S,11S,14R,15R)-2,15-Dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-5-yl (15Z)-tetracos-15-enoic acid | Generator | Cholesteryl 15-tetracosenoate | MeSH | Cholesteryl nervonate | MeSH |
|
---|
Chemical Formula | C51H90O2 |
---|
Average Molecular Weight | 735.2591 |
---|
Monoisotopic Molecular Weight | 734.694082124 |
---|
IUPAC Name | (1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl (15Z)-tetracos-15-enoate |
---|
Traditional Name | (1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl (15Z)-tetracos-15-enoate |
---|
CAS Registry Number | 60758-73-8 |
---|
SMILES | CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@]3([H])[C@]4([H])CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@]23[H])C1 |
---|
InChI Identifier | InChI=1S/C51H90O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-31-49(52)53-44-36-38-50(5)43(40-44)32-33-45-47-35-34-46(42(4)30-28-29-41(2)3)51(47,6)39-37-48(45)50/h14-15,32,41-42,44-48H,7-13,16-31,33-40H2,1-6H3/b15-14-/t42-,44+,45+,46-,47+,48+,50+,51-/m1/s1 |
---|
InChI Key | PUKCXSHDVCMMAN-FYGHJIOESA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as cholesteryl esters. Cholesteryl esters are compounds containing an esterified cholestane moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Steroid esters |
---|
Direct Parent | Cholesteryl esters |
---|
Alternative Parents | |
---|
Substituents | - Cholesteryl ester
- Cholesterol
- Cholestane-skeleton
- Delta-5-steroid
- Carboxylic acid ester
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
General References | - Oda E, Hatada K, Kimura J, Aizawa Y, Thanikachalam PV, Watanabe K: Relationships between serum unsaturated fatty acids and coronary risk factors: negative relations between nervonic acid and obesity-related risk factors. Int Heart J. 2005 Nov;46(6):975-85. [PubMed:16394593 ]
- Sala-Vila A, Castellote AI, Campoy C, Rivero M, Rodriguez-Palmero M, Lopez-Sabater MC: The source of long-chain PUFA in formula supplements does not affect the fatty acid composition of plasma lipids in full-term infants. J Nutr. 2004 Apr;134(4):868-73. [PubMed:15051839 ]
- Powell TL, Jansson T, Illsley NP, Wennergren M, Korotkova M, Strandvik B: Composition and permeability of syncytiotrophoblast plasma membranes in pregnancies complicated by intrauterine growth restriction. Biochim Biophys Acta. 1999 Aug 20;1420(1-2):86-94. [PubMed:10446293 ]
|
---|